Pfizer Has 41% Of Arthritis Market Post-Vioxx

Pfizer and FDA have agreed to "black box" for Bextra skin reactions and will address safety in post-op patients "separately" in new labeling. Pfizer plans NDA for parecoxib by the end of the year.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet